CRIS: Curis registers 320,369 shares for its 2026 Incentive Plan

Curis (CRIS) filed a Form S-8 to register 320,369 shares for its 2026 Incentive Plan, a routine equity compensation filing. The shares, with a par value of $0.01, are reserved for employees and directors, potentially increasing future supply. The filing also mentions a 1-for-20 reverse stock split effective July 2, 2026.

Original reporting
Published Nov 13, 2026, 9:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2026, 6:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CRIS
Bearish
medium confidence
Mentioned
$CRIS
Relevance
4/10
AlphAI data visualization · based on quantisnow.com
Decision brief

The 30-second read

$CRISBearishLow
01

Why it matters

The filing adds potential future share supply, creating dilution risk, while the reverse split may improve share price perception.

02

Market read

Routine equity compensation filing with modest dilution implications; limited trading relevance.

03

What to watch

The upcoming 1‑for‑20 reverse split could attract new investors seeking higher per‑share price, partially mitigating dilution concerns.

Relevance 4/10Novelty 3/10Timing: post filing

Background

Curis (CRIS) filed a Form S-8 to register shares for its 2026 Incentive Plan and announced a 1‑for‑20 reverse split effective July 2, 2026.

Company-level read

Ticker impact

$CRISBearishMedium confidence
Context

Form S-8 filing registers 320,369 shares for Curis' 2026 Incentive Plan, adding potential future dilution.

Expected impact

likely modest downward pressure as the market prices in dilution risk

Evidence & confidence

Equity compensation filings are routine but signal future share supply; investors typically react with slight price weakness.

Market effects

Minimal impact on the broader biotech sector; similar filings are common and do not shift sector dynamics.

None

Low

Counterpoint

If the reverse split boosts share price perception, the dilution may be offset, limiting downside.

Key entities

  • Curis, Inc.

    Biotech company filing the incentive plan registration.

Related articles

$CRISHigh

Curis Provides Third Quarter 2026 Business Update

CURIS INC (CRIS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2026 Business Update Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., November 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of

$CRISMed

Curis (CRIS) Q3 2026 Earnings Call Transcript

Curis (CRIS) reported Q3 2026 net loss of $8.1M, narrower than 2025. The company is advancing clinical trials for emavusertib in NHL and CLL, with initial data expected by year-end. They aim for accelerated approval submissions in 2027. Cash reserves are $5M, expected to fund operations into 2027.

$CRISMedAI 8/10

Curis Provides Third Quarter 2026 Business Update

Curis, Inc. (CRIS) reported Q3 2026 financial results, showing a net loss of $8.1M, and provided a business update. The company is conducting studies on emavusertib for CLL and PCNSL, with initial data expected in December 2026. Curis completed a public offering and a private placement, extending its cash runway into 2027. Management will host a conference call to discuss the update.

$CRISMedAI 8/10

Curis Prices $5.6 Million Offering Of Shares And Warrants; Stock Up

Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).

$CRISMed

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.

$CRISMedAI 8/10

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Curis (NASDAQ:C

Curis Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.